Schering-Plough Corporation (NYSE: SGP)

2000 Galloping Hill Rd.
Kenilworth, NJ 07033-0530 (Map)
Phone: 908-298-4000
Fax: 908-298-7653
http://www.sch-plough.com

Tools from our advertising partners:
Start A Franchise

Overview

Schering-Plough can get rid of the most embarrassing ailments -- runny noses, sunburned shoulders, and fungal feet. The pharmaceuticals giant makes prescription and OTC drugs, animal health products, and personal care products. Although it is best known for allergy medications Clarinex and Nasonex, the firm also specializes in anti-infectives and cancer drugs. Additionally, it co-promotes erectile dysfunction pill Levitra in the US with GlaxoSmithKline and cholesterol drug Vytorin with Merck. Schering-Plough's OTC offerings include Claritin allergy pills, Afrin nasal sprays, Dr. Scholl's foot care products, and sun care lines Coppertone and Bain de Soleil. The firm acquired Akzo Nobel's Organon unit in 2007.

Sample Overview & History

Key Numbers from Hoover's UK

Key financials for Schering-Plough Corporation (NYSE: SGP)

Company Type Public (NYSE: SGP)
Fiscal Year-End December
2007 Sales (mil.) £6,353.9
1-Year Sales Growth 19.8%
2007 Net Income (mil.) (£737.5)
2007 Employees 55,000
1-Year Employee Growth 64.2%
Get more Key Numbers
TIP: Want to stay abreast of the latest in IPO news? Sign up for Hoover's IPO Update newsletter and start receiving exclusive Hoover's content delivered straight to your inbox. Each newsletter is delivered weekly to help you stay ahead of the competition.
TIP: Subscribers have access to detailed financial data (income statement, balance sheet, cash flow) for more than 500,000 public and private companies in the UK.

Key People from Hoover's UK

Key people and executives for Schering-Plough Corporation (NYSE: SGP)

Chairman and CEO Fred Hassan
(Subscribers see complete biographies -- view sample)

Connect to this executive
EVP and CFO Robert J. Bertolini
Connect to this executive
SVP Business Development David A. Piacquad
Connect to this executive
Did you know... Hoover's new ConnectMail subscription add-on lets you send direct e-mail to millions of executives. Click here to learn more.

Top Competitors from Hoover's UK

Top competitors of Schering-Plough Corporation (NYSE: SGP)

There are 33 competitors for Schering-Plough; see more.
TIP: Analyze the Competitive Landscape to view a head-to-head comparison of a firm's profitability, operations, growth, and valuation versus that of its top three competitors.

Industry Information from Hoover's UK

First Research Industry Profiles Extensive Industry Intelligence

Hoover's Industries

More Industry Information
TIP: See what companies are creating the biggest impact each week with Hoover's Hottest Companies newsletter. Sign up now and start receiving exclusive Hoover's content delivered straight to your inbox. Each newsletter is delivered weekly to help you stay ahead of the competition.

Subsidiaries/Affiliates Covered By Hoover's UK

Subsidiaries/affiliates of Schering-Plough Corporation (NYSE: SGP)

TIP: Use subsidiary and affiliate information to determine easy cross-sell and upsell opportunities within an organization or business line. Hoover's subscribers have full access to detailed Family Tree information.

Rankings from Hoover's UK

See how Schering-Plough Corporation (NYSE: SGP) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones

  • #212 in FORTUNE 500
  • S&P 500
  • #394 in FT Global 500
TIP: Hoover's subscribers have access to FORTUNE 500 and other rankings that make targeted list building easy.

Subscribers Get More!

Search Hoover's UK

View Hoover's UK Free Content

Buy A Report on Schering-Plough:

Sample UK Subscriber Content


Bizmology

No Christmas wrapping on toy safety reforms

by Linnea Kirgan, Jan. 2nd, 2008
Read more at Bizmology.com.


Companies That Exceed Expectations

Who's going above and beyond the status quo? Learn more about these groundbreaking companies!

Current Edition: Click Here



Small Business Expert

Presented by Comcast Business Class

Read More from the Current Edition: Performance Reviews